Brain Cancer

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.

Phase 1 data may warrant further investigation of TLX101 plus external beam radiation therapy for patients with recurrent glioblastoma.

The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.

Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.

Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.

Developers plan to discuss findings from the phase 2/3 GBM AGILE study with the FDA to determine a potential approval pathway for paxalisib.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032.

The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma.

The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma.

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

Investigators also report an improvement in time to next intervention with vorasidenib compared with placebo among patients with IDH-mutated glioma in the phase 3 INDIGO trial.

Findings from a phase 1 trial highlight the potential tolerability and efficacy of ABM-1310 as a treatment for patients with BRAF-mutated solid tumors.

Overall survival is expected to continue improving among patients with glioblastoma being treated with frontline olaptesed pegol plus radiotherapy and bevacizumab who remain on the phase 1/2 GLORA study.

MDNA55 appears tolerable and effective in a cohort of patients enrolled in a phase 2b trial, showing sustained efficacy in subgroup analyses.

Data from a phase 2 trial assessing lenalidomide in patients under 22 years of age also highlight an optimal dose level for this population.

ERAS-801 is under investigation as part of the phase 1 THUNDERBBOLT-1 trial in a population of patients with EGFR-mutant, recurrent glioblastoma.

Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.

Treatment with tovorafenib appears well tolerated among pediatric patients with low-grade glioma, according to findings from the phase 2 FIREFLY trial.

In the study, 331 patients with IDH-mutated low-grade glioma were randomized to receive oral vorasidenib at 40 mg once daily or matched placebo in 28-day cycles.